

The following abstracts were presented either orally or as a poster at the AABB National Meeting in New Orleans, October 2009:

- a. Boothe G, Lyles AM, Langevin E, Lyles O, Wilkinson SL. **Results of a Targeted Donor Letter Campaign Informing Donors of the Local Hospital that Received Their Blood Product as an Attempt to Increase Donation Frequency.**
- b. Wilkinson SL, Schlumpf KD, Simon TL, Custer B. **Demographics of Successful Donation Visits and Deferral Visits at Six Blood Centers Over a Three-Year Period.**
- c. Schlumpf KS, Wilkinson SL, Simon TL, Wright D, Custer B. **Demographics of Deferred Donation Visits at Six Blood Centers Over a Three-Year Period.**
- d. Sinclair K, Campbell T, Carey PM, Langevin E, Bowser B, Tricaso J, France CR. **An Adapted Motivational Interview Enhances Donation Attitudes and Increases Retention.**
- e. Pinkard S, Carey PM. **Implementation and Efficacy of Photopheresis Instrumentation in Pediatric Patients.**
- f. Carey PM, Wilkinson SL, Steele WR, Wright DJ, Mast AE, Simon TL, Rio J. **Fixed Versus Mobile Site Donation Patterns by Donor Traits and Sponsor Type at 6 US Blood Centers 2006-2008.**
- g. Pinkard S, Carey PM. **The Use of Plasma Exchange in the Treatment of Pancreatitis Secondary to Familial Hypertriglyceridemia in Pediatric Patients.**
- h. Gottschall JL, Kleinman SH, Kakaiya R, Triulzi DJ, Busch MP, Carrick DM, Norris PJ, Carey PM, Hillyer CD, BR Curtis. **HNA Antibodies in Blood Donors.**
- i. Pinkard S, Carey PM. **Apheresis Procedure Management in Low Weight Pediatric Patients.**
- j. Carey PM, Wilkinson SL, Steele WR, Wright DJ, Mast AE, Simon TL, Rios J. **Fixed Versus Mobile Site Donation Patterns by Donor Traits and Sponsor Type at 6 US Blood Centers 2006-2008 .**
- k. Custer B, Schlumpf KS, Wright DJ, Wilkinson SL, Paul N. **Analysis of Return Behavior in Temporarily Deferred Blood Donors.**
- l. Davenport RD, Judd W, Downs T, Pehta JC, Banks K, Rugg N, Pratt PG, Worsham DN, Bailey M, Cancelas J. **The P-Capt Prion Filter Does Not Alter Red Cell Antigens.**
- m. Booth GS, Calimlim P, Ziman A, Lu Q, Goldfinger D, Yuan S. **A Retrospective Review of ABO Blood Grouping Discrepancies in an Academic Medical Center.**
- n. Rugg N, Cancelas J, Pratt PG, Worsham DN, Dunn SK, van der Meer PF. **Twenty-Four-Hour Hold of Whole Blood for PRP-Derived Components Does Not Impair the In Vitro Quality of RBC and Platelets.**
- o. Kline L, George G, Rugg N, Cancelas J. **In Vitro Evaluation of LEUKOSEP® HRC-600-C Leukocyte Reduction System for Red Blood Cells Prepared Within 48 Hours and Filtered on Day 3.**
- p. Cancelas J, Rugg N, Pratt PG, Worsham DN, Goodrich RP. **Red Cells from Riboflavin + UV-Light Treated Whole Blood Can Be Effectively Radiolabeled with 51Cr for Viability Studies.**
- q. Rugg N, Cancelas J, Pratt PG, Worsham DN, Dunn SK, van der Meer PF. **Twenty-Four-Hour Hold of Whole Blood for PRP-Derived Components Does Not Impair the In Vitro Quality of RBC and Platelets.**
- r. Steele WR, Johnson BR, Wright DJ, Schlumpf KS, Wilkinson SL. **A Comparison of Post Donation Information (PDI) Donors and Appropriately Deferred (AD) Donors: Are PDI Donors Different?**
- s. Wilkinson SL, Steele WR, Qiao HX, Wright DJ, Johnson BR. **Characteristics of Post-Donation Information (PDI) Donors: Demographics, Intervening Donations and Differences by PDI Reason.**
- t. Biswas HH, Kaidarova Z, Garratty G, Gible JW, Newman B, Smith J, Ziman A, Friley J, Sacher RA, Murphy EL. **Increased All-Cause and Cancer Mortality Associated with HTLV-II Infection.**
- u. Cancelas J, Rugg N, Pratt PG, Worsham DN, Dunn SK, Pehta JC, Mathews M, Banks K. **P-Capt Filtered RBC Maintain Adequate Hematological, Biochemical and In Vivo Recovery Levels After Storage.**
- v. Cancelas J, Rugg N, Friedman KD, Graminske S, Snyder EL, Corda T, Vassallo RR, Whitley PH, Fender L, Razatos A. **RBCs Collected on Trima Accel with Press-Through RBC Leukoreduction and Addition of Metered RBC Storage Solution Maintain In Vitro Quality and In Vivo Recovery.**
- w. Cable RG, Glynn SA, Gottschall JA, Kiss JE, Mast AE, Murphy EL, Simon TL, Sacher RA, Fang J, Wright DJ. **Predicting Iron Deficiency in Blood Donors.**
- x. Cable RG, Mast AE, Glynn SA, Gottschall JL, Kiss JE, Lee T, Busch MP, Murphy EL, Sacher RA, Carrick DM, Wright DJ. **Human Transferrin G277S Polymorphism is Not a Useful Predictor of Blood Donor Iron Deficiency.**
- y. Bickers VS, English PF, Wilkinson SL, Hughes L, Abshire E. **An Alternative to the Traditional Audit.**
- z. Kiss JE, Cable RG, Fang J, Mast AE, Gottschall JL, Simon TL, Wright DJ, Murphy EL, Carey PM, Sacher RA. **Laboratory Assessment of Iron Deficiency in Fingerstick Hemoglobin/Hematocrit-Accepted Blood Donors**

The following abstracts were presented at the 35 Annual ASHI Meeting in San Francisco, November 2009

- a. Girnita AL, Batal I, Teuteberg J, Bermudez C, Kormos R, Shullo M, McNamara D, Speziali G, Toyoda Y, Jelinek L, Lomago J, Zeevi A. **HLA-Specific Antibody Strength Determined by Solid-Phase Assays Correlates with Donor-Specific Crossmatches.**
- b. Lunz K, Abu-Elmagd, Martin D, Costa G, Girnita A, Zeevi A. **Immunosuppression Minimization in Multivisceral Transplant Recipients: The Impact on Global T Cell Immune Response.**
- c. Lunz L, Randhawa P, Howe J, Shapiro R, Girnita A, Zeevi A. **Detection of Serum Antibody in Renal Allografts with Focal Peritubular Capillary C4d Deposition.**
- d. Bentlejewski C, Feingold B, Girnita A, Webber S, Zeevi A. **Determination of Allosensitization by Multiple Assays and Associations within First Year Rejection.**
- e. Jelinek L, Lunz J, Lomago J, Howe J, Martell J, Duquesnoy R, Shapiro R, Girnita A, Zeevi A. **Case of AMR in a Renal Transplant Patient Who Exhibited an Anamnestic Antibody Response.**

The following abstracts were presented at the ASH Meeting in New Orleans, Dec 5-8, 2009.

- a. Chang KH, Sanchez-Aguilera A, Sengupta A, Arnett J, Dunn S, Williams DA, Cancelas JA. **Vav3 and Rac2 Activation Are Required for B Progenitor Transformation Induced by p190-BCR-ABL.**
- b. Gonzalez-Nieto D, Chang K-H, Kohler A, Arnett J, Li L, Ghiaur G, Sengupta A, Fishman GI, Gutstein DE, Civitelli R, Barrio LC, Gunzer M, Cancelas JA. **Connexin-43 expression regulates the migration of hematopoietic stem cells and progenitors towards and from bone marrow.**
- c. Guo G, Liu W, Chava K, Cancelas J, Thomas G, Kozma SC, Zheng Y. **Role of mTOR in hematopoiesis and hematopoietic stem cell regulation.**
- d. Gonzalez-Nieto D, Ghiaur G, Li L, Arnett J, Dunn S, Fishman GI, Gutstein DE, Civitelli R, Cancelas JA. **Connexin-43 regulates the cell cycle entry of hematopoietic stem cells within the stem cell niche.**
- e. Sengupta A, Arnett J, Dunn S, Cancelas JA. **Bmi-1 overexpression synergizes with p210-BCR-ABL to induce stem cell and progenitor transformation in vitro and in vivo.**
- f. Sengupta A, Arnett J, Dunn S, Cancelas JA. **Deletion of Rac2 GTPase inhibits proliferation of chronic myelogenous leukemia (CML) stem cells and progenitors (HSC/P) in vivo and promotes survival of Scl/p210-BCR-ABL mice.**
- g. Oaks J, Neviani P, Mukhopadhyay A, Santhanam R, Y Ma Y, Mao C, Marcucci G, Chen C-S, Cortes J, Caligiuri MA, Hokland Sr P, Huettner C, Koschmieder S, Cancelas J, Briesewitz R, Bhatia, D-C Roy R, Ogretmen B, Perrotti D. **FTY720 but not its immunosuppressive phosphorylated form FTY720-P exerts anti-leukemic activity towards Ph(+) and Ph(-) myeloproliferative disorders through reactivation of the PP2A tumor suppressor.**

The following articles have been published in a peer-reviewed journal:

- a. Murphy EL, Shaz B, Hillyer CDE, Carey PM, Custer BS, Hirschler N, Fang J, Schreiber GB. **NHLBI Retrovirus Epidemiology in Blood Donors Study-II(REDS-II). Minority and foreign-born representation among US blood donors; demographics and donation frequency for 2006.** Transfusion 2009;49:2221-8.
- b. Truiulzi DJ, Kleinman S, Kakaiya RM, Busch MP, Norris PJ, Steele WR, Glynn SA, Hillyer CD, Carey P, Gottschall JL, Murphy EL, Rios JA, Ness PM, Wright DJ, Carrick D, Schreiber GB. **The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: implications for a transfusion-related acute lung injury risk reduction strategy.** Transfusion 2009;49: 1825-35.
- c. Mahller YY, Williams JP, Baird WH, Mitton B, Grossheim J, Saeki Y, Cancelas JA, Ratner N, Cripe TP. **Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus.** PLoS ONE. 2009;4(1):e4235.
- d. Milsom MD, Lee AW, Zheng Y, Williams DA, Cancelas JA. **Fanca-/- haemopoietic stem cells demonstrate a mobilization defect which can be overcome by administration of the small molecule Rac inhibitor NSC23766.** Haematologica. 2009 Jul;94(7):1011-5.
- e. Cancelas JA, Williams DA. **Rho GTPases in hematopoietic stem cell functions.** Curr. Opin. Hematol., 2009 Jul;16(4):249-54.
- f. Sanchez-Aguilera A, Rattmann I, Drew DZ, Müller LU, Summey V, Lucas DM, Byrd JC, Croce CM, Gu Y, Cancelas JA, Johnston P, Moritz T, Williams DA. **RhoH GTPase is critical in the development of B-cell chronic lymphocytic leukemia.** 2009 Leukemia Epub Oct 22 2009.

- g. Yamada Y, Cancelas JA, Rothenberg ME. **Murine model of hypereosinophilic syndromes/chronic eosinophilic leukemia.** *Int Arch Allergy Immunol.* 2009;149 Suppl 1:102-7.
- h. Miller SJ, Lan ZD, Hardiman A, Wu J, Kordich JJ, Patmore DM, Hegde RS, Cripe TP, Cancelas JA, Collins MH, Ratner N. **Inhibition of Eyes Absent Homolog 4 expression induces malignant peripheral nerve sheath tumor necrosis.** *Oncogene.* 2009 Nov 9 (epub, ahead of print).
- i. Mulloy J, Cancelas JA, Filippi MD, Guo F, Zheng Y. **Rho GTPases in hematopoiesis.** *Blood* (accepted), 2009
- j. Sengupta A, Arnett J, Dunn S, Cancelas JA. **Rac activity is essential for stem cell-initiated chronic myelogenous leukemia in vivo.** *Blood*, submitted.
- k. Murphy E, Sacher R, et al. **Neurological abnormalities in HTLV-I and II infected individuals without overt myelopathy.** *Neurology*, In Press.
- l. Samavedi V, Sacher R. **Hematopoietic Stem Cell Transplantation.** *E-Medicine.* Updated November 6, 2009. <http://emedicine.medscape.com/article/208954-overview>
- m. Kanbar A, Sacher R. **Burkitt Lymphoma and Burkittlike Lymphoma.** *eMedicine.* Pending October 2009